OSR Health Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.8M-48.8% YoYTTM through 30 Jun 2026
Net Income -$14.9M-3,793.0% YoYTTM through 30 Jun 2026
Free Cash Flow -$7.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 35.3% |
| EBITDA Margin | -387.2% |
| Operating Margin | -933.7% |
| Net Margin | -824.4% |
Returns
-11.9%ROE
-8.9%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio0.18x
Net Debt-$955.6Knet cash position
Cash & Equivalents$1.5M
Quality Metrics
Altman Z-Score-0.64
Piotroski F-Score3 / 9
FCF Margin-398.3%
Multi-Year Trend
RevenueFY2025: $2.9M
Diluted EPS-$0.20TTMFY2024: $-1.12
Dividend
No dividend
Capital Allocation
R&D Spend$382.5K
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| RMC (Medical Device Distribution) | View detailsEvolving into a 4PL logistics model with a projected KRW 159.9 billion addressable market in targeted 4PL categories. | ||
| Vaximm (Oral Cancer Immunotherapy) | View detailsAdvancing oral immunotherapies for cancer treatment. | ||
| Darnatein (Design-Augmented Biologics) | View detailsAdvancing pre- or early clinical assets with emerging regulatory paths. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.